Journal
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
Volume 88, Issue 7, Pages 3101-3113Publisher
WILEY
DOI: 10.1111/bcp.15262
Keywords
cannabinoids; addiction medicine; epilepsy; neurology; prescribing; clinical pharmacology
Categories
Ask authors/readers for more resources
There is a growing international interest in providing consensus advice for prescribers in the field of drug resistant epilepsy, especially when it comes to trying potential therapies like cannabinoids that are nonregistered or off-label. In order to address the gap in practice and provide guidance, a working group in Australia developed interim consensus advice for prescribers, focusing on the use of cannabis medicines in the treatment of epilepsy and providing information on dosing, toxicity, and drug interactions. This interim consensus advice is expected to be updated as new evidence emerges and eventually form the basis for a subsequent Guideline.
There is international interest for consensus advice for prescribers working in the field of drug resistant epilepsy intending to trial potential therapies that are nonregistered or off-label. Cannabinoids are one such therapy. In 2017, the New South Wales State Government (Australia) set up a cannabinoid prescribing guidance service for a wide variety of indications, based on known pharmacology together with the relevant new literature as it became available. Increasing interest in cannabis medicines use outside this State over the following 5 years together with a paucity of registration-standard clinical trials, lack of information around dosing issues, drug interactions and biological plausibility meant there remained a large unmet need for such advice. To address the unmet need in epilepsy, and until medicines were registered or regulator quality data were available, it was agreed to bring together a working group comprising paediatric and adult epilepsy specialists, clinical pharmacists., clinical pharmacologists and cannabis researchers from across Australia to develop interim consensus advice for prescribers. Although interim, this consensus advice addresses much of the current practice gap by providing an informed overview of the different cannabis medicines currently available for use in the treatment of epilepsy in paediatric and adult settings, with information on dose, drug interactions, toxicity, type of seizure and frequency of symptom relief. As such it supplements the limited evidence currently available from clinical trials with experience from front-line practice. It is expected that this consensus advice will be updated as new evidence emerges and will provide guidance for a subsequent Guideline.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available